THTX Theratechnologies Inc. Quick Ratio

Theratechnologies Inc. (THTX) specializes in developing niche medications for immune system enhancement. This market valuation chart visualizes the risks of reduced insurance reimbursements and debt obligations amid weak cash flow, where the metric stands at 0.65. Stable revenue from HIV therapy is offset by costs associated with oncology research and development. Business success depends on government price regulation and the clinical trial outcomes of new products.

To build a resilient portfolio, I evaluate an issuer's ability to settle debts instantaneously. This metric measures the ratio of cash and accounts receivable to short-term liabilities, intentionally ignoring illiquid inventories. For Theratechnologies Inc. (THTX), this is critical, as the development of peptide drugs requires high capital mobility. Analyzing the acid-test ratio allows for the determination of the company's actual financial strength buffer.